ADHD Challenges Involve More Than Dopamine and Norepinephrine
- Thanks for this Guest Post from Lindsay Grude and Dr Kelly Olsen with the Research Team at NeuroScience up in Wisconsin.-
Common Sense
Attention deficit hyperactivity disorder (ADHD) is commonly associated with dysfunctional dopamine and norepinephrine neurotransmission, and most ADHD drugs target these neurotransmitters. [ed note: Intuniv, a new non-stimulant has added interest regarding the function of glutamate to the list of relevant ADHD neurotransmitters - and more about yet another one, PEA, in later postings.]
Glutamate Actions
Emerging research also implicates the neurotransmitter glutamate in the development of ADHD, likely due to its interaction with dopamine and norepinephrine. Current literature suggests that glutamate contributes to the development of ADHD through its interaction with dopamine neurotransmission. The striatum and prefrontal cortex, two regions of the brain that are implicated in ADHD, interact by exchanging dopamine and glutamate projections. The release of glutamate from the prefrontal cortex promotes responsiveness to external events, and elevations in glutamate signaling result in increased behavioral responsiveness to external events. Responding in a timely manner to changing stimuli is of course necessary, but excessive responsiveness may lead to constant shifting of attention. The striatum is likely the brain area that keeps this attention-shifting in check, as striatal dopamine released in the prefrontal cortex inhibits glutamate release from these neurons, thereby decreasing behavioral responsiveness to external stimuli.
As a result, inadequate dopamine neurotransmission from the striatum allows uncontrolled glutamate release, and the resultant excess glutamate signaling increases behavioral responsiveness to external stimuli, i.e. increases distractibility (Russell, 2003).
Following this line of reasoning, Ludolph et al. (2010) support the claim that excessive glutamate stimulation of the striatum from the prefrontal cortex results in the clinical manifestations of ADHD. Atomoxetine, a fairly new treatment for ADHD, was initially proposed to be effective through its support of norepinephrine transmission. However, Ludolph et al. found that the drug can also antagonize the N-methyl D-aspartate (NMDA) receptor, a type of glutamate receptor, and that this effect may have a role in atomoxetine’s success in treating ADHD.
Glutamate Relevance
It is also possible that a functional defect with glutamate receptors may contribute to the development of ADHD. In a study of spontaneously hypertensive rats (SHR), which are used as a model of ADHD, an abnormality in the NMDA receptor was found and thought to be a contributing factor to ADHD-related symptoms these rats display (Lehohla, 2003). SHRs have been used as an ADHD model to test glutamate α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors as well. Russell (2001) demonstrated in both SHR and control rats that glutamate injection into the prefrontal cortex caused norepinephrine release and determined that AMPA receptor stimulation on noradrenergic terminals was responsible.
More importantly, the study also found that the glutamate-stimulated release of norepinephrine was more pronounced in SHR compared to control rats. It is clear from the growing body of research that glutamate plays a role in the development of ADHD. Excessive glutamate release in the striatum increases behavioral responsiveness to external stimuli, and abnormalities in glutamate receptors have been associated with symptoms of ADHD.
However, the degree to which glutamate contributes to ADHD is yet unknown. It is imperative that future research explores this pathway, as the manipulation of dopamine and norepinephrine is simply not effective for everyone. In the quest to develop more effective drugs to treat ADHD, glutamate will hopefully be more frequently spotlighted as a potential target.
———————————
Thanks to the NS team!
cp
———————————
References
– Ludolph AG, Udvardi PT, Schaz U, Henes C, Adolph O, Weigt HU, Fegert JM, Boeckers TM, Föhr KJ. Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. Br J Pharmacol. 2010 May;160(2):283-91.
– Lehola M, Kellaway L, Russell VA. NMDA receptor function in the prefrontal cortex of a rat model for attention-deficit hyperactivity disorder. Metab Brain Dis. 2004 Jun;19(1-2):35-42.
– Russell VA. Increased AMPA receptor function in slices containing the prefrontal cortex of spontaneously hypertensive rats. Metab Brain Dis. 2001 Dec;16(3-4):143-9.
– Russell VA. Dopamine hypofunction possibly results from a defect in glutamate-stimulated release of dopamine in the nucleus accumbens shell of a rat model for attention deficit hyperactivity disorder–the spontaneously hypertensive rat. Neurosci Biobehav Rev. 2003 Nov;27(7):671-82. Review.
Related articles
- Intuniv Answers: ADHD Neurotransmitters – Glutamate Matters (corepsychblog.com)
- Brain chemical finding could open door to new schizophrenia drugs (sciencedaily.com)
- When Memory Starts Working (thebeautifulbrain.com)
- Lab Discovery Could Lead to New Meds for Psychosis (psychcentral.com)
- How the ultimate smart phone sends text messages: Neurotransmitters. (didyouseemycrotch.wordpress.com)
- Pitfalls in the Diagnosis of Adult ADHD (brainposts.blogspot.com)

Digitally available now at Nook, Kindle, Barnes and Noble.
ADHD Medication Rules – PDF For Your Desktop
ADHD Medication Rules | Paying Attention To The Meds For Paying Attention – Kindle Version










Pingback: Tracking the Days of our Lives « ADD . . . and-so-much-more
Pingback: Tweets that mention ADHD And Glutamate: Neurotransmitters Evolve | CorePsych Blog -- Topsy.com